BR112023002129A2 - Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma - Google Patents

Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma

Info

Publication number
BR112023002129A2
BR112023002129A2 BR112023002129A BR112023002129A BR112023002129A2 BR 112023002129 A2 BR112023002129 A2 BR 112023002129A2 BR 112023002129 A BR112023002129 A BR 112023002129A BR 112023002129 A BR112023002129 A BR 112023002129A BR 112023002129 A2 BR112023002129 A2 BR 112023002129A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
same
aquaporin
aquaporin inhibitor
Prior art date
Application number
BR112023002129A
Other languages
English (en)
Portuguese (pt)
Inventor
Qian Yong
Shi Ruiwen
Liu Amy
Song Tian
Liu Yanhong
Feng Aijuan
Ren Jinsheng
Original Assignee
Jiangsu Simcere Pharm Co Ltd
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharm Co Ltd, Aeromics Inc filed Critical Jiangsu Simcere Pharm Co Ltd
Publication of BR112023002129A2 publication Critical patent/BR112023002129A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023002129A 2020-08-05 2021-08-04 Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma BR112023002129A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010779964 2020-08-05
PCT/CN2021/110506 WO2022028459A1 (en) 2020-08-05 2021-08-04 Pharmaceutical composition of aquaporin inhibitor and preparation method thereof

Publications (1)

Publication Number Publication Date
BR112023002129A2 true BR112023002129A2 (pt) 2023-04-18

Family

ID=80120008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002129A BR112023002129A2 (pt) 2020-08-05 2021-08-04 Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma

Country Status (12)

Country Link
US (1) US20230293556A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192442A4 (cg-RX-API-DMAC10.html)
JP (1) JP7877294B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230137284A (cg-RX-API-DMAC10.html)
CN (1) CN117337182A (cg-RX-API-DMAC10.html)
AU (1) AU2021323181A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002129A2 (cg-RX-API-DMAC10.html)
CA (1) CA3187716A1 (cg-RX-API-DMAC10.html)
IL (1) IL300341A (cg-RX-API-DMAC10.html)
MX (1) MX2023001493A (cg-RX-API-DMAC10.html)
TW (1) TW202228714A (cg-RX-API-DMAC10.html)
WO (1) WO2022028459A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
AU2017261828B2 (en) 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
WO2024208207A1 (zh) * 2023-04-03 2024-10-10 拜西欧斯(北京)生物技术有限公司 一种双取代萘化合物及其药物组合物和用途
WO2025075479A1 (ko) * 2023-10-04 2025-04-10 이화여자대학교 산학협력단 아쿠아포린 4 억제제의 심방세동 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7626042B2 (en) * 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
US9316633B2 (en) * 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
SG11201604477SA (en) * 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
AU2017261828B2 (en) * 2016-05-13 2023-04-13 Aeromics, Inc. Crystals

Also Published As

Publication number Publication date
EP4192442A1 (en) 2023-06-14
TW202228714A (zh) 2022-08-01
MX2023001493A (es) 2023-06-23
WO2022028459A1 (en) 2022-02-10
US20230293556A1 (en) 2023-09-21
JP7877294B2 (ja) 2026-06-22
JP2023536509A (ja) 2023-08-25
KR20230137284A (ko) 2023-10-04
IL300341A (en) 2023-04-01
CN117337182A (zh) 2024-01-02
AU2021323181A1 (en) 2023-03-23
EP4192442A4 (en) 2025-03-19
CA3187716A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2023001493A (es) Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma.
BR112023021383A2 (pt) Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo
EP4595965A3 (en) Heteroalkyl dihydroquinoline sulfonamide compounds
Hendriks et al. Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities
EP1158985A1 (en) OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
BRPI0213570B8 (pt) cristal na forma alfa de acetanilida e composição farmacêutica sólida que a compreende
US20120149706A1 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
UA104471C2 (uk) ФАРМАЦЕВТИЧНА ДОЗОВАНА ФОРМА ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕННЯ ІНГІБІТОРУ СІМЕЙСТВА Bcl-2
BRPI0409227A (pt) composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto
WO1999032111A1 (en) INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
DE10017480A1 (de) Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
JP2025507472A5 (cg-RX-API-DMAC10.html)
MX2025008424A (es) Formulacion de lanifibranor
MX2024008371A (es) Compuestos organicos deuterados y usos de los mismos
AR133698A1 (es) COMPUESTOS Y COMPOSICIONES COMO AGENTES DEGRADANTES DE CBP / p300 Y USOS DE ESTOS
BR112023025221A2 (pt) Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
WO2023150790A3 (en) Novel and highly selective sars-cov-2 mpro inhibitors
MX2025010949A (es) Derivados de ciclohexanona fusionados con tiofeno sustituido, composiciones que comprenden los mismos y su uso como productos farmacéuticos
ES2396764B1 (es) FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
MX2023001742A (es) Agente terapeutico para la enfermedad de higado graso.
AR046143A1 (es) Composicion farmaceutica que contiene un derivado de tiourea con solubilidad y biodisponiblidad mejoradas
BR112021014881A2 (pt) Composto de poliol anti-hipertensivo e derivados do mesmo

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]